Anaplastic thyroid cancer（ATC）is one of the most aggressive cancers in humans. Typical therapeutic approaches for malignant neoplasms such as surgery, radiotherapy, chemotherapy and combination therapy have been tried as a radical or palliative therapy for ATC patients, but outcomes are extremely poor. Recently, lenvatinib, which is a multi-targeted tyrosine kinase inhibitor, was approved as a new therapeutic drug for ATC. Here we report a case of ATC treated by lenvatinib.
The patient was an 80-year-old man who developed swelling of the frontal neck. Computed tomography showed that a thyroid tumor, which was diagnosed as anaplastic carcinoma by biopsy, involved the common carotid artery. Lenvatinib was administered for this unresectable case, and the tumor shrank significantly after starting administration. However, four months later, the tumor progressed rapidly and he died due to ATC.
As is generally known, ATC has a very poor prognosis. Lenvatinib could be the treatment of choice for ATC.
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